<DOC>
	<DOC>NCT01080638</DOC>
	<brief_summary>Intracoronary bolus Abciximab single is non-inferior to intravenous and continuous 12- hours infusion in the size reduction of infarction on cardiac magnetic resonance in Non-ST elevation Myocardial infarction.</brief_summary>
	<brief_title>Intracoronary Bolus Only Compared With Intravenous Bolus and 12-hours Infusion of Abciximab in Non-ST Elevation Myocardial Infarction.</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Abciximab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Immunoglobulin Fab Fragments</mesh_term>
	<mesh_term>Krestin</mesh_term>
	<criteria>nonST segment elevation acute myocardial infarction within 48 hours presence of chest pain TroponinT or I positive before CAG First myocardial infarction will be performed coronary angioplasty under 18 years of age,80 years or older Bleeding tendency History of major surgery within 4 weeks Major stroke within 2 years Thrombocytopenia (&lt;120,000 / uL) Cardiogenic shock Known allergy to aspirin, heparin, or abciximab Contraindication of MRI at study entry (implanted pacemakers, defibrillators, intracranial metallic implants etc) Chronic atrial fibrillation Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>abciximab</keyword>
	<keyword>Myocardial Infarction</keyword>
	<keyword>angioplasty</keyword>
	<keyword>Platelet</keyword>
</DOC>